Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

177
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
177
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

125
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
125
Statistical Significance01:50

Statistical Significance

20.1K
Once data is collected from both the experimental and the control groups, a statistical analysis is conducted to find out if there are meaningful differences between the two groups. A statistical analysis determines how likely any difference found is due to chance (and thus not meaningful). In psychology, group differences are considered meaningful, or significant, if the odds that these differences occurred by chance alone are 5 percent or less. Stated another way, if we repeated this...
20.1K
Hazard Ratio01:12

Hazard Ratio

111
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
111
Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

2.3K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
2.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Epidemiology and burden on the National Health Service of cardiomyopathy associated with transthyretin amyloidosis based on administrative health data.]

Recenti progressi in medicina·2026
Same author

Extreme Cardiovascular Risk and LDL-C Target Achievement in People With HIV.

Open forum infectious diseases·2026
Same author

Single-catheter radiofrequency pulmonary vein isolation for atrial fibrillation: a comparative evaluation.

Frontiers in cardiovascular medicine·2026
Same author

Blood pressure control in people with HIV and established atherosclerotic cardiovascular disease: a real-world descriptive analysis.

AIDS (London, England)·2026
Same author

Sex Differences in the Usefulness of Unattended Blood Pressure Measurement in Patients with Arterial Hypertension.

High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension·2026
Same author

[Eugene Braunwald obituary].

Giornale italiano di cardiologia (2006)·2026

Related Experiment Video

Updated: Jun 23, 2025

Author Spotlight: Integrated Multi-Omics Analysis for Unveiling Multicellular Immune Signatures in Clinical Heart Attack Cohorts
08:51

Author Spotlight: Integrated Multi-Omics Analysis for Unveiling Multicellular Immune Signatures in Clinical Heart Attack Cohorts

Published on: September 20, 2024

1.2K

[How to interpret subgroup analyses in cardiovascular trials?]

Christian Basile1, Aldo Pietro Maggioni2

  • 1Division of Cardiology, Department of Medicine, Karolinska Institutet, Stoccolma, Svezia - Dipartimento di Scienze Biomediche Avanzate, Università degli Studi di Napoli "Federico II", Napoli.

Giornale Italiano Di Cardiologia (2006)
|June 25, 2024
PubMed
Summary

Subgroup analyses in clinical trials examine treatment effects across diverse patient groups. This review offers a critical approach for interpreting these analyses in cardiovascular research, emphasizing a priori definitions and statistical power.

More Related Videos

In Silico Clinical Trials for Cardiovascular Disease
09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

1.7K
Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

5.3K

Related Experiment Videos

Last Updated: Jun 23, 2025

Author Spotlight: Integrated Multi-Omics Analysis for Unveiling Multicellular Immune Signatures in Clinical Heart Attack Cohorts
08:51

Author Spotlight: Integrated Multi-Omics Analysis for Unveiling Multicellular Immune Signatures in Clinical Heart Attack Cohorts

Published on: September 20, 2024

1.2K
In Silico Clinical Trials for Cardiovascular Disease
09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

1.7K
Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

5.3K

Area of Science:

  • Cardiovascular Medicine
  • Clinical Trial Methodology
  • Biostatistics

Background:

  • Clinical trials assess treatment efficacy in overall populations, often assuming uniform effects across patient subgroups.
  • Subgroup analyses are crucial for understanding treatment effect variability based on patient characteristics (age, sex, etc.).
  • These analyses address practical questions regarding treatment decisions and benefit/risk profiles in specific subpopulations.

Purpose of the Study:

  • To propose a critical framework for interpreting subgroup analyses within cardiovascular clinical trials.
  • To highlight the importance of a priori definition, biological plausibility, and limited scope for subgroup analyses.
  • To guide researchers in evaluating the credibility and implications of subgroup findings, especially in neutral or negative overall studies.

Main Methods:

  • Review of principles and best practices for conducting and interpreting subgroup analyses in clinical research.
  • Emphasis on the distinction between a priori and post-hoc subgroup analyses.
  • Discussion of statistical power requirements when heterogeneity is anticipated in specific patient subgroups.

Main Results:

  • Subgroup analyses are most relevant when overall trial results show significant treatment differences.
  • Significant findings in neutral or negative trials should be treated as exploratory.
  • Post-hoc subgroup analyses require cautious interpretation and external consistency for credibility.

Conclusions:

  • A structured, critical approach is necessary for interpreting subgroup analyses in cardiovascular trials.
  • Adherence to predefined, biologically plausible hypotheses enhances the validity of subgroup findings.
  • Sufficient statistical power is essential for subgroup analyses, particularly when treatment effect heterogeneity is expected.